Thalidomide for treatment of patients with chronic graft-versus-host disease

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Chronic graft-versus-host disease (cGVHD) is a significant complication following allogeneic stem cell transplantation.
• Patients in this study had poor-prognosis cGVHD, indicated by thrombocytopenia or evolution from acute GVHD.
• Standard initial therapy involved glucocorticoids plus either cyclosporine or tacrolimus.

Purpose of the Study:

• To evaluate the safety and tolerability of thalidomide as an initial therapy for extensive chronic graft-versus-host disease (cGVHD).
• To assess the feasibility of incorporating thalidomide into the initial treatment regimen for cGVHD.

Main Methods:

• A randomized, placebo-controlled, double-blind trial was conducted.
• Patients received either thalidomide or placebo, combined with glucocorticoids and either cyclosporine or tacrolimus.
• Thalidomide was initiated at 200 mg/day, with potential escalation to 800 mg/day.

Main Results:

• Thalidomide was discontinued early in 92% of patients, compared to 65% for placebo (P = .02).
• Neutropenia and neurological symptoms were the primary reasons for early thalidomide discontinuation.
• The treatment duration was insufficient to evaluate thalidomide's efficacy in controlling cGVHD.

Conclusions:

• Early discontinuation due to adverse events limited the assessment of thalidomide's efficacy in cGVHD.
• Further studies are needed to determine the optimal use and long-term safety of thalidomide in cGVHD management.